INTRODUCTION: Bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies. In addition to reviewing the epidemiology of transitional cell carcinoma (TCC), we review the current status and the future directions of bladder cancer prevention. MATERIALS AND METHODS: A literature review of peer-reviewed articles which address bladder cancer prevention was performed. RESULTS: Pre-clinical and limited clinical data suggest that bladder cancer is responsive to efforts to delay or prevent its development in at-risk patients, and in reducing the risk of recurrence in patients with established disease. Many epidemiologic studies, however, investigating natural products, such as vitamins and herbal compounds, lack conclusive evidence of their chemopreventive effects. CONCLUSIONS: While many agents hold promise in the prevention of bladder cancer, none currently can be recommended as proven chemoprevention strategies. Improving the accuracy of patient risk assessment and identification of surrogate endpoint biomarkers are crucial to the testing of these strategies. Efficient study design will ensure rapid and substantial advances in the chemoprevention of bladder cancer.
INTRODUCTION:Bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies. In addition to reviewing the epidemiology of transitional cell carcinoma (TCC), we review the current status and the future directions of bladder cancer prevention. MATERIALS AND METHODS: A literature review of peer-reviewed articles which address bladder cancer prevention was performed. RESULTS: Pre-clinical and limited clinical data suggest that bladder cancer is responsive to efforts to delay or prevent its development in at-risk patients, and in reducing the risk of recurrence in patients with established disease. Many epidemiologic studies, however, investigating natural products, such as vitamins and herbal compounds, lack conclusive evidence of their chemopreventive effects. CONCLUSIONS: While many agents hold promise in the prevention of bladder cancer, none currently can be recommended as proven chemoprevention strategies. Improving the accuracy of patient risk assessment and identification of surrogate endpoint biomarkers are crucial to the testing of these strategies. Efficient study design will ensure rapid and substantial advances in the chemoprevention of bladder cancer.
Authors: Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner Journal: World J Urol Date: 2006-11 Impact factor: 4.226
Authors: Leah M Ferrucci; Rashmi Sinha; Mary H Ward; Barry I Graubard; Albert R Hollenbeck; Briseis A Kilfoy; Arthur Schatzkin; Dominique S Michaud; Amanda J Cross Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: James M Hotaling; Jonathan L Wright; Gaia Pocobelli; Parveen Bhatti; Michael P Porter; Emily White Journal: J Urol Date: 2011-02-22 Impact factor: 7.450
Authors: Mi-Sung Kim; Jong-Eun Kim; Do Young Lim; Zunnan Huang; Hanyong Chen; Alyssa Langfald; Ronald A Lubet; Clinton J Grubbs; Zigang Dong; Ann M Bode Journal: Cancer Prev Res (Phila) Date: 2013-12-10
Authors: João C Fernandes; José Sereno; Patricia Garrido; Belmiro Parada; Maria F X Cunha; Flávio Reis; Manuela E Pintado; Alice Santos-Silva Journal: Mar Drugs Date: 2012-12 Impact factor: 5.118